A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Modulating the host immune response during tuberculosis is an emerging and critical advance in the therapeutic approach. Here the authors present data from a first-in-human phase I/II randomised trial on the safety and immunogenicity of adjuvant therapy of the H56:IC31 vaccine and cyclooxygenase-2 i...
Guardado en:
Autores principales: | Synne Jenum, Kristian Tonby, Corina S. Rueegg, Morten Rühwald, Max P. Kristiansen, Peter Bang, Inge Christoffer Olsen, Kjersti Sellæg, Kjerstin Røstad, Tehmina Mustafa, Kjetil Taskén, Dag Kvale, Rasmus Mortensen, Anne Ma Dyrhol-Riise |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6152a3f5e03b4794a0706ed5b7ac2925 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IC - Editorial Board
Publicado: (2021) -
Acta No. 56
por: Banco Central de Chile
Publicado: (2019) -
Resolución 56: Transporte marítimo = Resolution 56: Maritime transport
Publicado: (2014) -
IC-Behavior: An interdisciplinary taxonomy of behaviors.
por: Kai R Larsen, et al.
Publicado: (2021) -
CEPAL Review no.56
Publicado: (2015)